Vanberra Signal

Cardea Sciences

Curated by Signal

Monitoring device to identify heart failure risks

Overview

Cardea Sciences is focussed developing a non-invasive heart monitoring device to identify patients at risk of suffering from heart failure & other cardiovascular events. Its flagship product is a monitoring device that detects atrial fibrillation patients who will not be able to tolerate the arrhythmia and will suffer from symptoms at an early stage. The company was the winner of WBENC National Pitch Competition, Falling Walls Lab NY & 4D CTSA Technology Development award. As of November 2016, the product details are not disclosed.

Key facts

Founded
2016

Business model

Contact

More on Vanberra Signal

Members only

Competitors & similar companies

More Life Sciences Technology companies
  • Developer of fetal heart rate monitoring device

    Life Sciences TechnologyAtlanta, United States
  • Provider of cannabis growers with genetically certified cannabis clones

    Life Sciences TechnologySan Jose, United States
  • Provider of wearable neonatal signs monitor

    Life Sciences TechnologyChicago, United States

About Cardea Sciences

What does Cardea Sciences do?

Cardea Sciences is focussed developing a non-invasive heart monitoring device to identify patients at risk of suffering from heart failure & other cardiovascular events.

Where is Cardea Sciences headquartered?

Cardea Sciences is headquartered in New York City, United States.

When was Cardea Sciences founded?

Cardea Sciences was founded in 2016.

Which sector is Cardea Sciences in?

Cardea Sciences operates in Life Sciences Technology.

Who are Cardea Sciences's competitors?

Companies similar to Cardea Sciences include Libi Medical, Conception Nurseries, and Neopenda.